NSCLC Stage IV Clinical Trial
Official title:
Predictive Prognostic Factors in Patients With Non-small Cell Lung Cancer Stage IV
This study is a cohort study with patients with advanced NSCLC. Patients will answer questionnaires about symptoms and quality of life and will be submitted to physical and blood tests, and computer tomography. The aim of this study is to estimate prognostic factors predicting survival to 3 months in patients with advanced NSCLC.
Non-small-cell lung cancer (NSCLC) is currently the neoplasm leading in deaths worldwide and
in Brazil. NSCLC has a high incidence, is usually diagnosed in advanced stages and has poor
survival rates. The ability to refine the prognosis of a disease has implications at the time
of diagnosis and decision about treatment. Clinical and laboratory factors are studied to
evaluated the prognosis of diseases. Palliative Prognostic Score (PaP score), Karnofsky
Performance Status Scale (KPS), Palliative Prognostic Index (PPI) are applied in patients
with many types of solid tumors. The Charlson Score evaluates comorbidities and the
attributed risk for presence it. Others predictors of prognostic are cachexia, quality of
life, inflammatory factors, sarcopenia. There is a need to improve the ability to estimate
the prognosis and to identify the factors responsible to low survival rates in patients with
NSCLC diagnosed at advanced stage, also as a tool for a better treatment selection.
This is an observational and prospective study, including patients diagnosed with NSCLC and
admitted in ICESP, staged as IV at admission, with no previous systemic treatment and
classified as ECOG 2-4. Demographic data, presence of a caregiver, anthropometry, MRC dyspnea
scale, KPS, Edmont Symptom Scale, Charlson's Comorbidity Score, PPI and PaP were evaluated in
each patient. Evaluation of sarcopenia and cachexia with abdominal CT (Slice-O-Matic, v.5),
arm circumference, handgrip strength test and quality of life using EORTC score QLQ C-30 and
QLQ-CAX-24 were also evaluated. Significant prognostic factors will be selected by
multivariate analysis in a training set estimated as 217 patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05543330 -
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04106180 -
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
|
Phase 2 | |
| Recruiting |
NCT05215548 -
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
|
Phase 2 | |
| Recruiting |
NCT04042558 -
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
|
Phase 2 | |
| Completed |
NCT04507217 -
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
|
Phase 2 | |
| Recruiting |
NCT04467801 -
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
|
Phase 2 | |
| Active, not recruiting |
NCT04027647 -
Phase 2 Study of Dacomitinib in NSCLC
|
Phase 2 | |
| Recruiting |
NCT04768491 -
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
|
||
| Not yet recruiting |
NCT04492969 -
Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
|
||
| Recruiting |
NCT04116918 -
Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
|
||
| Terminated |
NCT03411473 -
Study of AGEN1884 With Pembrolizumab in 1L NSCLC
|
Phase 2 | |
| Recruiting |
NCT03564197 -
18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC
|
N/A | |
| Not yet recruiting |
NCT06219317 -
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
|
Phase 2 | |
| Not yet recruiting |
NCT04604470 -
Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
|
||
| Recruiting |
NCT05132218 -
Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
|
||
| Not yet recruiting |
NCT04136535 -
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
|
Phase 2 | |
| Completed |
NCT03184571 -
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
|
Phase 2 | |
| Completed |
NCT06339554 -
Alectinib-induced Endocrine Toxicity
|
||
| Active, not recruiting |
NCT04549428 -
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
|
Phase 2 | |
| Recruiting |
NCT03647956 -
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors
|
Phase 2 |